SCHEMBL6763802

SCHEMBL6763802

COC(=O)CCc1ccccc1Sc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.52
LMNA P02545 4/20 0.48
ALDH1A1 P00352 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
BLM P54132 1/20 0.48
NOD2 Q9HC29 1/20 0.48
MMP2 P08253 4/20 0.45
MMP9 P14780 4/20 0.45
MMP12 P39900 4/20 0.45
MMP14 P50281 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6761108 0.88 MMP2 (0.46) LMNAALDH1A1MMP2MMP9MMP12
SCHEMBL6761043 0.83 SLC6A4 (0.54) SLC6A4LMNAALDH1A1NPSR1BLM
SCHEMBL6762198 0.82 AGBL2 (0.49) LMNAALDH1A1NPSR1L3MBTL1KDM4E
SCHEMBL6762867 0.80 LMNA (0.46) SLC6A4LMNAALDH1A1NPSR1BLM
SCHEMBL6763776 0.80 SMN1; SMN2 (0.41) MAPTTDP1CYP11B1CYP11B2
SCHEMBL4982350 0.79 CYP11B1 (0.51) ALDH1A1MAPTHDAC1HDAC8HDAC6
SCHEMBL8910954 0.78 MAPT (0.43) LMNAALDH1A1NPSR1L3MBTL1KDM4E
SCHEMBL23666455 0.77 SLC6A4 (0.54) SLC6A4LMNAALDH1A1NPSR1BLM
SCHEMBL6763799 0.77 LMNA (0.47) SLC6A4LMNAALDH1A1NPSR1BLM
SCHEMBL6761155 0.76 LMNA (0.46) SLC6A4LMNAALDH1A1NPSR1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 SLC6A4 3871/4885LMNA 2027/4885ALDH1A1 510/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 SLC6A4 3871/4885LMNA 2027/4885ALDH1A1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.